Company news

Recce Pharmaceuticals Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Patient Dosing Underway in Ph 3 Indonesia DFI Trial

September 25, 2025

Preliminary Final Report

August 29, 2025

R327G Highly Effective in Burn Wounds Model

August 12, 2025

Recce Signs Debt Facility with Avenue Capital Group

June 17, 2025

Successful Placement of Entitlement Offer Shortfall

June 3, 2025

China Patent Accepted for RECCE Anti-Infectives

May 26, 2025

Recce Enters into USA Department of Defense R&D Agreement

April 27, 2025

Recce Pharmaceuticals Receives Approval for Additional Phase II Trial of RECCE® 327 Topical Gel for Diabetic Foot Infections

April 23, 2025

Entitlement Offer - Offer Booklet and Access Letter

April 22, 2025

Phase II Clinical Trial Receives Additional Approval for DFI

April 22, 2025

Recce Pharmaceuticals Announces A$5.0 million Placement & Launches A$10.8 million Entitlement Offer to Shareholders

April 10, 2025

Placement and Entitlement Offer to Fund Phase III Trials

April 10, 2025

Key Opinion Leader Presentation

March 2, 2025

Recce Pharmaceuticals Granted Japanese Patent for RECCE® Anti-Infectives

February 27, 2025

Japan Patent Allowance for RECCE Anti-Infectives

February 25, 2025

Recce Pharmaceuticals Reports Positive Data from Phase II Trial of RECCE® 327 Gel in Acute Bacterial Skin and Skin Structure Infections, Supporting Accelerated Commercialization Pathway

February 19, 2025

Positive Phase II Data from Clinical Trial of R327 Gel

February 16, 2025

Trading Halt

February 13, 2025

Pause in Trading

February 13, 2025

Correction to Appendix 4C and Quarterly Activities Report

February 6, 2025

Patient Dosing Complete in Phase II ABSSSI Trial of R327G

January 20, 2025

Regulatory Approval for Registrational Phase 3 R327G Trial

December 8, 2024

Australia Patent Granted for RECCE Anti-Infectives

November 25, 2024

AUD $6.75m R&D Rebate Approved

November 13, 2024

Ethics Approval for Registrational Ph3 R327G Clinical Trial

November 10, 2024

AGM Presentation

November 5, 2024

Phase II ABSSSI Clinical Trial Advances to Final Stages

November 4, 2024

Efficacy Data & Approval to Continue Ph II ABSSSI Trial

October 27, 2024

Ph II ABSSSI Trial Recruitment and Dosing Passes Halfway

October 8, 2024

Notice of Special General Meeting/Proxy Form

October 8, 2024

Recce Pharmaceuticals Announces Successful Completion of Share Purchase Plan

August 6, 2024

Successful Completion of Share Purchase Plan

August 4, 2024

Recce Pharmaceuticals Receives $2 Million Grant from U.S. Department of Defense for RECCE® 327 Gel

July 16, 2024

US Department of Defense Grants US $2m for R327G

July 15, 2024

R327 Efficacy against WHO Priority Pathogen Acinetobacter B

July 8, 2024

Placement & SPP to raise $10 million - Funded to FY26

July 2, 2024

Phase I/II UTI/Urosepsis Rapid Infusion Trial Complete

June 27, 2024

Ethics Approval Broadens to All Topical Infections

June 24, 2024

Further R&D Rebate Approved

June 18, 2024

R327 added to WHO List of Antibacterial Products

June 18, 2024

Cohort Dosing Complete Ph I/II UTI/Urosepsis Clinical Trial

June 10, 2024

Ph I/II UTI/Urosepsis Trial Dosing Commenced in Next Cohort

May 15, 2024

MCRI Pilot Study- Positive Efficacy Data for Lung Infections

May 9, 2024

China Patent Granted for RECCE Anti-Infectives

May 6, 2024

Safety Committee Approves High Dose of 4,000mg

April 26, 2024

Recce Completes 5,000 R327 Doses Per Week under GMP

April 16, 2024

Recce Pharmaceuticals - Business Update

April 7, 2024

Patent Granted in Israel for RECCE Anti-Infectives

April 2, 2024

Next Cohort Dosing Ph I/II UTI/Urosepsis Clinical Trial

March 12, 2024

Recce Receives AUD $11.17m R&D Advance

March 7, 2024

← Newer news releases · Older news releases →

Decks

The 5 newest of 45 decks. Every deck is listed under its year.